Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk amid investor concerns that the Danish ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

June 9 (Reuters) - Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk (NOVOb.CO), opens new tab amid investor concerns that the Danish drugmaker has lost its first ...

London-based Parvus is interested in influencing the appointment of a new chief executive officer, according to the Financial Times. Have a confidential tip for our reporters? Get in Touch ...

Parvus, known for past campaigns involving Ryanair and UniCredit, is seeking to influence the selection of Novo Nordisk’s new CEO, the report said, citing people with knowledge of the details.